



February 24, 2026

To: Office of Compounding Quality and Compliance Office of Compliance Center for Drug Evaluation and Research U.S. Food and Drug Administration *Submitted via email to:*
compoundinginspections@fda.hhs.gov

Subject: Response to Warning Letter

This letter serves as our formal, written response to the Warning Letter issued to MaxLife Technologies Inc., dated February 20, 2026.

We take this matter very seriously and have taken immediate action to address the violations observed on our website, <https://maxlife.com>. We understand our responsibility to ensure that our operations comply with all requirements of federal law, including FDA regulations.

As requested below is an explanation of the specific steps we have taken to address the violations and prevent their recurrence:

1. Identifying Producing Entities

We have identified the specific entities that produce the compounded products offered on our website.

2. Providing Representative Labeling

We have reviewed and corrected the product images on our website that previously identified "Maxlife" on the pictured label.

3. Addressing and Removing False or Misleading Claims

We have conducted a comprehensive review of our website content and have modified or removed claims that could be construed as false or misleading under FDCA §§ 502(a) and 502(bb). Specifically, we have removed the following statements:

- Claims that our offerings are a "generic compounded medication".
- Any statements asserting our compounded treatments are "FDA Approved".
- Claims stating our treatments have the same active ingredient as Wegovy, Ozempic®, Mounjaro, and Zepbound.
- References to "Active ingredients in Ozempic® & Wegovy®".
- References to "Active ingredients in Mounjaro® & Zepbound®".

We acknowledge that compounded drug products are not FDA-approved, and we have ensured our website no longer implies that our products have been FDA-approved or evaluated for safety and effectiveness.

We are fully committed to maintaining ongoing compliance and preventing the recurrence of these or other violations. If you require any additional information or further documentation as you continue to assess our activities and practices, please let us know.

Best,

A handwritten signature in black ink, appearing to read 'Farhad Karimkhani', with a stylized, flowing script.

Farhad Karimkhani

CEO

MaxLife Technologies Inc. dba Maxlife